Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562137 | 1.00 | GRM2 (0.74) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL4559074 | 1.00 | GRM2 (0.74) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL750114 | 0.85 | GRM2 (1.00) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL15754732 | 0.85 | GRM2 (0.58) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL4561328 | 0.84 | GRM2 (1.00) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL748588 | 0.84 | GRM2 (0.98) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL7032057 | 0.84 | GRM2 (0.76) | GRM2 | |
| SCHEMBL4559281 | 0.84 | GRM2 (0.76) | GRM2 | |
| SCHEMBL15754382 | 0.84 | GRM2 (0.76) | GRM2 | |
| SCHEMBL749295 | 0.83 | GRM2 (0.75) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661435-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2012062759-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | GRM2 1/4885CYP2C9 2477/4885CYP2C19 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.